[Corrections] Correction to Lancet HIV 2025; 12: e473–84

Ryan P, Blanco JL, Masia M, et al. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. Lancet HIV 2025; 12: e473–84—In table 1 of this Article, data for “Previous AIDS (CDC criteria): No” in the dolutegravir and lamivudine group should have been 215 (78%). This has been corrected as of July 1, 2025.